

Daniel L Morganstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7930733/publications.pdf>

Version: 2024-02-01

20
papers

610
citations

933447

10
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

1138
citing authors

#	ARTICLE	IF	CITATIONS
1	Thyroid abnormalities following the use of cytotoxic Tâ€lymphocyte antigenâ€4 and programmed death receptor proteinâ€1 inhibitors in the treatment of melanoma. <i>Clinical Endocrinology</i> , 2017, 86, 614-620.	2.4	165
2	Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3621-3634.	3.6	136
3	Receptor Interacting Protein 140 Regulates Expression of Uncoupling Protein 1 in Adipocytes through Specific Peroxisome Proliferator Activated Receptor Isoforms and Estrogen-Related Receptor Î±. <i>Molecular Endocrinology</i> , 2007, 21, 1581-1592.	3.7	87
4	Human fetal mesenchymal stem cells differentiate into brown and white adipocytes: a role for ERRÎ± in human UCP1 expression. <i>Cell Research</i> , 2010, 20, 434-444.	12.0	64
5	Immunotherapy-induced endocrinopathies: assessment, management and monitoring. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881989618.	3.2	29
6	Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. <i>BMC Cancer</i> , 2015, 15, 163.	2.6	25
7	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021, 70, 1904-1913.	12.1	24
8	Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. <i>Clinical Medicine</i> , 2020, 20, 163-168.	1.9	21
9	Endocrine toxicity of cancer immunotherapy: clinical challenges. <i>Endocrine Connections</i> , 2021, 10, R116-R124.	1.9	16
10	Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4903-e4916.	3.6	15
11	Prevalence of diabetes in patients admitted to a cancer hospital. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 178-180.	0.6	9
12	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4139-TPS4139.	1.6	4
13	UK recommendations for<i>SDHA</i>germline genetic testing and surveillance in clinical practice. <i>Journal of Medical Genetics</i> , 2023, 60, 107-111.	3.2	4
14	Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1336.e9-1336.e12.	1.7	3
15	Diabetes and cancer: Optimising glycaemic control. <i>Journal of Human Nutrition and Dietetics</i> , 2023, 36, 504-513.	2.5	3
16	Role of nuclear receptor coregulators in metabolism. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 797-807.	2.4	2
17	Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. <i>Lancet Oncology</i> , The, 2021, 22, 905-907.	10.7	2
18	Pituitary enlargement following ipilimumab without long term endocrine dysfunction. <i>Current Problems in Cancer</i> , 2021, 45, 100710.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Cancer and diabetes: new links and new challenges. Practice Nursing, 2013, 24, 392-395.	0.1	0
20	Adrenal insufficiency and checkpoint inhibitors for cancer. Clinical Medicine, 2020, 20, e139.1-e139.	1.9	0